News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
ALS patients experience neuroinflammation and rapid neurodegeneration
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Subscribe To Our Newsletter & Stay Updated
